Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Age as a cancer risk factor: biomarkers, prevention, and clinical trial endpoints

Miriam Merad • 25 Oct 2026
ESMO 2026
General

Miriam Merad, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, highlights the concept of age as a risk factor for cancer and the potential for prevention through identification of biomarkers and targets, such as increased IL-1, which can also be associated with cognitive decline and cardiovascular events. A more global approach is needed to understanding age-associated diseases, including cancer, and designing cancer trials with composite endpoints that incorporate cardiovascular events and cognitive decline will also be essential. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Miriam Merad

How is age a risk factor for cancer and can it be a treatable target?
1:42
How is age a risk factor for cancer and can it be a treatable target?
Miriam Merad • 25 Oct 2026
Utilizing imaging and biomarkers to identify people at risk of cancer
1:24
Utilizing imaging and biomarkers to identify people at risk of cancer
Miriam Merad • 25 Oct 2026

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
What financial challenges patients and healthcare systems face in oncology?
1:11
What financial challenges patients and healthcare systems face in oncology?
Daniel Goldstein • 23 Oct 2026
How can we enhance the efficacy of TILs therapy in solid tumors?
2:27
How can we enhance the efficacy of TILs therapy in solid tumors?
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals